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Research suggests that targeting high-risk, nonhypertensive pa-
tients for preventive intervention may delay the onset of hyperten-
sion. We aimed to develop a biomarker-based risk prediction mod-
el for assessing hypertension risk in an urban Han Chinese popula-
tion.
Methods
We analyzed data from 26,496 people with hypertension to ex-
tract factors from 11 check-up biomarkers. Then, depending on a
5-year follow-up cohort, a Cox model for predicting hypertension
development was built by using extracted factors as predictors. Fi-
nally,  we created a hypertension synthetic  predictor  (HSP) by
weighting each factor with its risk for hypertension to develop a
risk assessment matrix.
Results
After factor analysis, 5 risk factors were extracted from data for
both men and women. After a 5-year follow-up, the cohort of par-
ticipants had an area under receiver operating characteristic curve
(area under the curve [AUC]) with an odds ratio (OR) of 0.755
(95% confidence interval [CI], 0.746–0.763) for men and an OR
of 0.801 (95% CI, 0.792–0.810) for women. After tenfold cross
validation,  the  AUC  was  still  high,  with  0.755  (95%  CI,
0.746–0.763) for men and 0.800 (95% CI, 0.791–0.810) for wo-
men. An HSP-based 5-year risk matrix provided a convenient tool
for risk appraisal.
Conclusion
Hypertension could  be  explained by 5  factors  in  a  population
sample of Chinese urban Han. The HSP may be useful in predict-
ing hypertension.
Introduction
Hypertension is a worldwide public health challenge because of its
high frequency and concomitant risks of cardiovascular disease
and renal disease (1). Many studies have demonstrated that life-
style modification can prevent high blood pressure, providing a ra-
tionale for the identification of high-risk participants so that early
lifestyle intervention strategies can be implemented to prevent hy-
pertension (2–4). In recent years, researchers have established hy-
pertension prediction models for different populations, including
Americans (5–8), Iranians (9), and Chinese (10,11). The 2 studies
of a Chinese population prediction model (10,11) had areas under
the curve (AUCs) that ranged from 71.6% to 73.5%. Inability to
incorporate enough laboratory biomarkers and existing recall bias
from questionnaire variables limited the effect of the 2 prediction
models. This study corrects these limitations. Prevalence, aware-
ness, treatment, and control of hypertension in China, a develop-
ing country, differs from that of developed countries (12,13). The
purpose of this study was to develop a biomarker-based risk-pre-
diction  model  for  hypertension  in  a  population  of  urban  Han
Chinese adults.
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Methods
Of 95,785 people aged 18 to 88 years who received annual medic-
al examinations from 2005 through 2010 at the Center for Health
Management of Shandong Provincial QianFoShan Hospital and
Shandong Provincial Hospital, 26,496 were diagnosed with hyper-
tension at their first check-up. Of 69,289 people without hyperten-
sion at baseline, 17,471 (10,239 men and 7,232 women) who re-
ceived annual clinical and laboratory examinations were selected
as a 5-year follow-up cohort.
We selected 11 biomarkers to analyze from the routine health
check-ups.  They were body mass index (BMI),  systolic  blood
pressure (SBP),  diastolic  blood pressure (DBP),  fasting blood
glucose (FBG), triglycerides (TG), high-density lipoprotein cho-
lesterol  (HDL-C),  hemoglobin (Hb),  hematocrit  (HCT),  white
blood cell count (WBC), lymphocyte count (LC), and neutrophil
granulocyte count  (NGC).  These biomarkers  have been previ-
ously associated with hypertension: BMI (14–16), SBP and DBP
(17), FBG (18), TG (16), HDL-C (19,20), Hb and HCT (21), and
WBC, LC, and NGC (22).
We measured the  height  and weight  of  participants  who were
wearing light clothing and no shoes. BMI was calculated as weight
(kg) divided by height squared (m2). SBP and DBP were meas-
ured using Omron HEM-907 (QuickMedical) by the cuff-oscillo-
metric method in the right arm of seated participants after a 5-
minute rest period. Two measurements were taken, and the 2 BP
values were averaged. Peripheral blood samples were obtained in
the morning after a 12-hour fast to measure the following bio-
markers: FBG, TG, HDL-C, Hb, HCT, WBC, LC, and NGC. The
study was approved by the Ethics Committee of School of Public
Health, Shandong University, and written informed consent was
obtained from all participants.
Hypertension was defined as diastolic blood pressure of 90 mm
Hg or more, systolic blood pressure of 140 mm Hg or more, or re-
ported use of medication known to treat hypertension. Age and
biomarkers were presented by mean (standard deviation), and Stu-
dent’s t test was used to distinguish between participants with and
without baseline hypertension.
First, to eliminate multicollinearity between the routine check-up
biomarkers and to extract risk-related factors of hypertension from
them, we used factor analysis with principal component algorithm
and varimax rotation from correlation matrix. The criteria for re-
taining factors were set up as eigenvalue of higher than 1. Further
analytical interpretation used biomarkers that share a factor load-
ing of at least 0.50. Second, on the basis of the cohort design, the
Cox proportional hazards regression model was built between the
hazard function of hypertension and the extracted latent factors:
hi(t) = h0(t)exp(β0agei+β1Fi1+β2Fi2+…+βkFik)
where hi(t) is the hazard rate for the ith subject at time t, and h0(t)
is the baseline hazard at time t. Then, a hypertension synthetic pre-
dictor (HSP) was derived by weighting each factor with its regres-
sion coefficients using the formula
HSP = β1F1+β2F2+…+βkFk.
After that, we calculated an HSP for each participant. Third, on the
basis of the cohort design, the Cox proportional hazards regres-
sion model was built again between the hazard function of hyper-
tension and the calculated HSP:
hi(t) = h0(t)exp(θ0age + θ1HSP)
The predictive probability of hypertension at year t was calculated
by the following formula:
where θ = θ0age + θ1HSP
Fourth, we used MedCalc software (23) for analysis of receiver
operator characteristics (ROC) curve, sensitivity, specificity, and
significance (P value) to evaluate the prediction effect. Finally, for
each participant from the 5-year cohort study, we calculated relat-
ive absolute risk (RAR) using the following equation:
where Pj(t) known as absolute risk (AR), was the probability of
hypertension at year t, in which j denoted the participant’s age.
signified the average probability of hypertension at year t in
j t h age, which can be calculated by the following model:
where  ,   was the mean of HSP in j t h
age.
All data analyses in this study were conducted for both men and
women. We used ArcGIS 9.1 (Esri) to depict the HSP-based 5-
year risk matrix for hypertension risk appraisal. All statistical ana-
lyses were performed using SAS version 9.2 (SAS Institute, Inc),
and significance was set at P < .05.
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Results
In our study, 26,496 of 95,785 participants had hypertension at
baseline, a prevalence of 27.7% (32.6% for men and 19.5% for
women). Although hypertension prevalence increased with age in
both men and women (Figure 1), it was higher in men than wo-
men before age 60 and was similar after age 60. Of the 3,793 par-
ticipants (2,894 men and 899 women) who did not have hyperten-
sion at baseline but had hypertension at the end of year 5, the cu-
mulative incidence was 21.7% (3,793 of 17,471). We calculated
the distribution of age and 11 biomarkers among participants with
and without baseline hypertension (Table 1),  and all  variables
differed significantly for participants with and without baseline
hypertension. Results of the analysis were used to create a correla-
tion matrix for the 11 biomarkers (Appendix A).
Figure 1. Prevalence of hypertension, by age, at baseline, in an urban Han
population, China, 2005–2010.
 
After exploring factor analysis (EFA), 5 latent factors were extrac-
ted from 11 biomarkers. Combined with explained variance and
cumulative variance, factor loadings by principal component ana-
lysis  with  varimax rotation  (Table  2).  Five  latent  risk-related
factors  could  explain  72.21%  of  total  variance  for  men  and
72.47% for  women:  inflammatory  factor  (IF),  blood viscidity
factor (BVF), insulin resistance factor (IRF), blood pressure factor
(BPF), and lipid resistance factor (LRF). Of the 5 factors, IF was
contributed by WBC and LC and NGC, BVF by Hb and HCT, IRF
by FBG and TG, BPF by SBP and DBP, and LRF by BMI and
HDL-C.
ROC curves for hypertension prediction models are in Figure S1
(Appendix B). The AUC was up to 75.5% for men and 80.1% for
women (Figure 2, graphs A1 and A2 for men and graphs B1 and
B2 for women), and was 75.5% and 80.0% after tenfold cross val-
idation. These matrices provide a convenient tool for hyperten-
sion prediction in clinical and health management. For example, if
a man aged 40 came to a hospital for a checkup, and 11 routine
health check-up biomarkers (BMI, SBP, DBP, FBG, TG, HDL-C,
Hb, HCT, WBC, LC, NGC) were tested, his HSP could be calcu-
lated using the formula in Figure 2. After that, we find his abso-
lute risk (AR) and RAR in (graphs A1 and A2) through his age
and his HSP. AR shows his predictive probabilities for hyperten-
sion are more than 5, and RAR shows his hypertension risk com-
pared with his peers (people aged 40).
Figure 2.  The 5-year risk matrix  for  risk appraisal  of  hypertension by sex.
Graphs  A1  and  B1  are  absolute  risk  matrices  for  men  and  women,
respectively; graphs A2 and B2 are relative absolute risk matrices for men and
women,  respectively.  The dashed lines indicate discrimination criteria  of
absolute risk for  predicting hypertension;  the curved lines indicate mean
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Discussion
In our study, the prevalence of hypertension was higher among
men (32.6%) than women (19.5%) at baseline. However, hyper-
tension prevalence changes with age. Hypertension prevalence
rises more steeply in aging women than in men, perhaps because
of hormonal changes during menopause (24–26).
Distribution of age and 11 routine health check-up biomarkers of
participants with and without baseline hypertension differed signi-
ficantly. After factor analysis, 5 latent factors were extracted from
11 biomarkers, not only eliminating the multicollinearity, but also
explaining the specific pathogenesis of hypertension. The 5 factors
were used to predict hypertension in the following prediction mod-
el. The 5 factors are the inflammatory factor (IF), blood viscidity
factor (BVF), insulin resistance factor (IRF), blood pressure factor
(BPF), and lipid resistance factor (LRF) in both men and women,
according to our analysis. The cumulative explained variances of
the 5 latent factors were 72.21% for men and 72.47% for women.
IF and BVF in particular were identified as the key factors for the
variation of  hypertension (IF contributes 23.54% for  men and
24.64% for women; BVF, 15.78% for men and 15.58% for wo-
men). Similar results have been found in other studies. Evidence
from human and animal studies suggests that inflammation leads
to the development of hypertension and that oxidative stress and
endothelial dysfunction are involved in the inflammatory cascade
(27). The elevation in blood viscosity could increase peripheral
resistance and play a role in the pathogenesis of essential hyper-
tension (28–30).
Two hypertension  prediction  models  have  been  developed  in
Chinese populations. Although the power of these prediction mod-
els  (AUC range:  71.6%–73.5%) was  acceptable,  their  risk  al-
gorithm and visualization of risk assessment still had room for im-
provement. Our HSP-based prediction model had better predic-
tion effect (ROC, 75.5% for men and 80.1% for women; ROC
after tenfold cross validation, 75.5% for men and 80.0% for wo-
men.). One reason our results were more accurate is because we
used laboratory biomarkers rather than questionnaire variables to
avoid recall bias. Another reason is that we used both factor ana-
lysis and the Cox model, producing a better model for hyperten-
sion prediction. Finally, we developed a risk matrix with AR and
RAR to represent risk assessment, which was convenient for prac-
tical application (Figure 2). For example, men and women who re-
ceive a routine health check-up can learn their AR from the risk
matrix. Comparing their results with those of other same-age parti-
cipants may warn patients of their risk and guide their choice of
nonpharmacologic measures to prevent hypertension. A limitation
to our study was that  all  participants were urban Han Chinese
adults; therefore, our results may not be generalizable to other
populations. More validation studies for these prediction models
are needed.
This is the first hypertension prediction model developed for urb-
an Han Chinese adults. Because of the large sample size, the es-
timates from our prediction model were stable, as demonstrated by
the tenfold cross validation. Physicians can use the HSP-based 5-
year hypertension risk matrix to measure patients’ risk for hyper-
tension, inform patients of their risks, help them choose appropri-
ate nonpharmacologic measures to prevent hypertension, and aid
in clinical counselling and decision making.
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Tables
Table 1. Distribution of Age and the 11 Biomarkers for Participants With and Without Baseline Hypertension, China, 2005–2010
Variable
Without Baseline Hypertension (n =
69,236)
With Baseline Hypertension (n =
26,478)
P ValuesaMean (SD)
Age, y 41.37 (12.37) 53.62 (14.24) <.001
Body mass index, kg/m2 24.27 (3.59) 26.86 (3.49) <.001
Systolic blood pressure, mmHg 117.4 (12.53) 149.2 (16.29) <.001
Diastolic blood pressure, mmHg 70.84 (9.24) 86.30 (12.73) <.001
Fasting blood-glucose, mmol/L 5.20 (1.11) 5.80 (1.60) <.001
Triglycerides, mmol/L 1.49 (1.32) 2.06 (1.79) <.001
High-density lipoprotein cholesterol, mmol/L 1.33 (0.33) 1.30 (0.36) <.001
Hemoglobin, g/L 146.7 (15.51) 151.1 (14.40) <.001
Hematocrit, % 43.61 (4.05) 44.74 (3.79) <.001
White blood cell count, 109/L 6.46 (1.59) 6.85 (1.68) <.001
Lymphocyte, 109/L 2.07 (0.61) 2.15 (0.71) <.001
Neutrophil granulocyte, 109/L 3.84 (1.23) 4.11 (1.26) <.001
aP values were calculated using Student’s t test.
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Table 2. Factor Loadings by Principal Component Analysis With Varimax Rotation on 11 Routine Health Check-up Biomarkers in Hy-
















BMI 0.0630 0.0978 0.3681 0.1534 −0.6950a 0.1000 0.0486 0.3131 0.2556 −0.6194a
SBP 0.0527 −0.1677 −0.0245 0.8540a 0.0113 0.0419 −0.0574 0.7988a 0.1902 0.0234
DBP −0.0003 0.3203 0.1370 0.7064a −0.0595 0.0114 0.1837 0.7549a −0.1657 −0.1249
FBG 0.0342 −0.0994 0.6782a 0.0696 −0.0777 0.0785 0.0423 0.0011 0.7670a −0.0739
TG 0.0836 0.1380 0.7850a −0.0029 0.1003 0.0807 0.0798 0.0356 0.7250a −0.0163
HDL-C −0.0650 −0.0171 0.2468 0.0761 0.8323a −0.0431 −0.0120 0.0782 0.0574 0.8778a
Hb 0.0627 0.9574a 0.0450 0.0333 −0.0550 0.0639 0.9705a 0.0542 0.0920 −0.0403
HCT 0.1242 0.9472a −0.0234 0.0332 −0.0425 0.1146 0.9651a 0.0674 0.0640 −0.0138
WBC 0.9906a 0.0718 0.0431 0.0355 −0.0512 0.9872a 0.0747 0.0170 0.0626 −0.0957
LC 0.6468a 0.0577 0.0850 −0.0199 −0.0306 0.6524a 0.0637 0.0837 0.1971 0.0990
NGC 0.8548a 0.0544 0.0036 0.0589 −0.0454 0.8577a 0.0571 −0.0277 −0.0327 −0.1728
% Variance
explained
0.2354 0.1578 0.1260 0.1060 0.0969 0.2464 0.1558 0.1237 0.1037 0.0951
Cumulative
variance
0.2354 0.3932 0.5192 0.6252 0.7221 0.2464 0.4022 0.5259 0.6296 0.7247
Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; Hb, hemoglobin; HCT, hematocrit; HDL-C, high-
density lipoprotein cholesterol; IR, insulin resistance; LC, lymphocyte; NGC, neutrophil granulocyte; SBP, systolic blood pressure; TG, triglycerides; WBC, white blood
cell count.
a Factor loading >0.5.
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Appendix A. Correlation Matrix Between 11 Biomarkers, Urban Han Population, China, 2005–2010. This file is available for download
as a Microsoft Word document at http://www.cdc.gov/pcd/issues/2015/docs/15_0192_AppendixA.doc [DOC – 41 KB].
 
Appendix B. Receiver Operator Characteristics (ROC) Curves for Hypertension Prediction Models, Urban Han Population, China,
2005–2010.
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